The tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) was found to be a potent genotoxic agent, in the V79 cell line, when activated by liver and lung homogenates from polychlorinated biphenyl (Aroclor)-treated adult Syrian golden hamsters. The damage was observed in the metaphase as well as in the anaphase--telophase divisions. Liver and lung homogenates from non-induced adult hamster were less effective in activating NNK. Micronuclei were also induced by NNK activated by fetal liver and lung homogenates from fetuses on the 15th day of gestation. The observed aberrations: micronuclei, chromatid aberrations particularly chromatid-type exchanges, anaphase bridges with or without acentric fragments, were concentration (8-40 mM NNK)-dependent. A significant number of aberrations were observed. These results suggest that NNK induces chromosome damage when activated by adult and fetal tissues. This damage could play, at least in part, a role in the NNK-induced carcinogenesis observed in vivo and underlines the importance of this compound in the transplacental carcinogenesis induced by tobacco smoke.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/carcin/9.12.2319 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tumour heterogeneity and personalized treatment screening based on single-cell transcriptomics.
Comput Struct Biotechnol J
December 2024
School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, Guangdong 518107, China.
According to global cancer statistics for the year 2022, based on updated estimates from the International Agency for Research on Cancer, there were approximately 20 million new cases of cancer in 2022 alongside 9.7 million related deaths. Lung, breast, colorectal, gastric, and liver cancers are the most common types of cancer.
View Article and Find Full Text PDFPrognostic value of liver metastasis in patients with esophageal squamous cell carcinoma treated with nivolumab.
Oncol Lett
March 2025
Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Kyoto 602-8566, Japan.
Nivolumab has been approved for unresectable recurrent advanced esophageal cancer. The present study aimed to provide real-world data on diverse patient profiles, including the elderly and those with poor performance status, while exploring therapeutic efficacy biomarkers. This retrospective study included 42 patients with esophageal cancer who received nivolumab after second- or later-line treatment at Kyoto Prefectural University of Medicine (Kyoto, Japan) from February 2020 to December 2021.
View Article and Find Full Text PDFUnveiling the link between chronic inflammation and cancer.
Metabol Open
March 2025
Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, 576104, Karnataka, India.
The highly nuanced transition from an inflammatory process to tumorigenesis is of great scientific interest. While it is well known that environmental stimuli can cause inflammation, less is known about the oncogenic modifications that chronic inflammation in the tissue microenvironment can bring about, as well as how these modifications can set off pro-tumorigenic processes. It is clear that no matter where the environmental factors come from, maintaining an inflammatory microenvironment encourages carcinogenesis.
View Article and Find Full Text PDFHigher 3-year recurrence-free survival rate in patients with complete pathological remission following neoadjuvant chemotherapy plus immunotherapy for esophageal cancer: a two-center, propensity score matching study.
Front Oncol
January 2025
Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, China.
Background: Neoadjuvant therapy is preferentially recommended for resectable locally advanced esophageal malignancies, with patients who achieve pathological complete response (PCR) anticipated to have longer survival rates. The aim of this study was to compare 3-year follow-up data for patients with esophageal malignancy who achieved PCR through neoadjuvant chemotherapy (nCRT) and to compare the findings with those of neoadjuvant immunotherapy plus chemotherapy (nICT).
Methods: This retrospective study included 85 patients with esophageal cancer who underwent surgical resection following nCRT (n=47) or nICT (n=38) between January 1, 2016 and January 1, 2020 at Fujian Medical University Union Hospital and Gaozhou People's Hospital.
Development and Validation of a Competitive Risk Model in Elderly Patients with Transitional Cell Bladder Carcinoma.
Med Sci Monit
January 2025
Department of Urology, Ningbo Municipal Hospital of Traditional Chinese Medicine (TCM), Affiliated Hospital of Zhejiang Chinese Medical University, Ningbo, Zhejiang, China.
BACKGROUND Transitional cell bladder carcinoma (tcBC) is the predominant form of bladder cancer, making up around 95% of reported cases. Prognostic factors for older individuals with tcBC differ from those affecting younger patients. The main purpose of this study was to establish a prognostic competing risk model for elderly patients with tcBC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!